CTNM

Over the past six months, Contineum Therapeutics' stock price has been influenced by several events. The company released Q4 2025 earnings in March 2026, reporting a net loss of $15.2 million, and Q1 2026 results in May 2026 with a net loss of $14.5 million, with Q2 2026 financial results announced in July 2026. Clinical trial updates included the initiation of patient dosing in the PROPEL-IPF global Phase 2 trial for PIPE-791 in Q1 2026, and topline data from an exploratory Phase 1b chronic pain trial for PIPE-791 in Q2 2026, which met safety objectives and showed pain improvements. Johnson & Johnson completed enrollment for the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder, but on September 14, 2026, the stock dropped significantly after J&J announced that this trial failed to meet its primary endpoint. In December 2025, the company completed an underwritten public offering, raising approximately $84.2 million in equity. Analyst coverage includes 'Buy' ratings from RBC Capital and Stifel Nicolaus, a 'Hold' from Morgan Stanley, and Goldman Sachs reinitiated coverage on September 24, 2026, classifying it as an Early-Stage Biotech company. Over the last month, the stock decreased by 8.90%, while over the last year, it increased by 6.53%, with a 52-week high of $17.79 and a low of $8.60.